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Bronchoalveolar lavage (BAL) has only a limited role in diagnosis of idiopathic pulmonary
fibrosis (IPF). A finding of raised neutrophils (>5%) and eosinophils (>2%) is characteristic
but not diagnostic of IPF. BAL cell count does not clearly differentiate between fibrotic non-
specific interstitial pneumonia and IPF either diagnostically or prognostically. BAL in IPF should
be considered in all patients with suspected infection, malignancy or acute exacerbations. In
such cases, it may be diagnostic. Because of few and conflicting results BAL fluid analysis has
very little clinical relevance determining prognosis and response to treatment in IPF.
ª 2010 Elsevier Ltd. All rights reserved.Bronchoalveolar lavage
Pulmonary diseases have traditionally been evaluated by
clinical data, laboratory tests, lung function tests,
imaging procedures and tissue biopsies. Bronchoalveolar
lavage (BAL), performed during fiberoptic bronchoscopy,
is a useful adjunct to lung biopsy in the diagnosis of
nonneoplastic lung diseases in a limited number of
settings. There are no absolute contraindications to the
performance of BAL beyond those commonly associated
with bronchoscopy. BAL is able to provide cells and
solutes from the lower respiratory tract and may provide
important information about diagnosis and yield insightssci, Clinica Pneumologica,
onza, Via Pergolesi 33, 20052
mib.it (A. Pesci).
0 Elsevier Ltd. All rights reservedinto immunologic, inflammatory, and infectious processes
taking place at the alveolar level.1 BAL, when combined
with clinical data and high-resolution computed tomog-
raphy of the chest, can facilitate the diagnosis of various
diffuse lung diseases. BAL is an excellent method of
obtaining specimens to rule out malignancy and infec-
tions, particularly opportunistic infections in immuno-
compromised hosts by pathogenic organisms not known to
colonize the lower respiratory tract.1 Examination of BAL
cells or acellular components of BAL via gene microarray
technology or proteomic analyses may allow BAL to
assume a more prominent role in diagnosis and manage-
ment of lung disease in the near future.
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing
interstitial lung disease of unknown etiology characterized
by progressive dyspnea, reduced lung volumes, impaired.
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interstitial pneumonia (UIP). IPF is included in idiopathic
interstitial pneumonia (IIP). The disease follows a relent-
lessly course. Mean survival time from the diagnosis is
2.5e3.5 years. In the event of rapid worsening of the
patient’s condition, the differential diagnosis between an
acute exacerbation and complications is vital. Because of
its poor prognosis and no established effective therapy, the
differential diagnosis of IPF from other IIP is important.2
Bronchoalveolar lavage in idiopathic
pulmonary fibrosis
BAL is a milestone in IPF respiratory research
It is beyond the scope of this text to address IPF patho-
genesis in any detailed fashion as this has been done in
other major references2 so only a few comments will be
made here. Bronchoalveolar lavage has been enormously
helpful in elucidating the key immune effector cells driving
the inflammatory response in IPF.1 Increase in poly-
morphonuclear leukocytes, neutrophil products, eosino-
phils, eosinophil products, activated alveolar macrophages,
alveolar macrophage products, cytokines, chemokines,
growth factors for fibroblasts, and immune complexes have
been noted in BAL of patients with IPF.1 Because compo-
nents retrieved in BAL fluid are in close proximity to
diseased tissue the study of cells and proteinaceous
substances in BAL continues to provide insight into the
pathogenesis and host immunity responses involved in
inflammation, fibrosis, and acute injury.
BAL for diagnosis of IPF
In the patients suspected to have UIP, the pattern of
inflammatory cells identified may be helpful in narrowing
the differential diagnosis of fibrosing interstitial pneumo-
nias but is not diagnostic of IPF. The BAL fluid analysis in IPF
typically shows an increase in total cell count, poly-
morphonucleated neutrophils (>5%), and eosinophilsTable 1 Bronchoalveolar lavage cell counts in idiopathic
pulmonary fibrosis.
Source No of
patients
Cell/
ml  105
Ly % Neu % Eo %
Welker L
et al., 20043
112 3.4 11.0 6.0 2.0
Kinder BW
et al., 20084
156 nd 8.0 6.0 2.0
Veeraraghavan S
et al., 20035
35 2.4 4.0 9.0 7.0
Tabuena RP
et al., 20056
81 1.74 3.2 1.0 0.4
Ryu YJ
et al., 20067
67 nd 5.5 7.0 nd
X mean 451 2.51 6.34 5.8 2.85
Ly Z lymphocytes; Neu Z neutrophils; Eo Z eosinophils.(>2%).1,2 These data were confirmed in studies conducted
after the recent classification3e7 (Table 1).
It has been shown that there is no correlation between
the percentage of various cell types found in BAL of IPF
patients and various clinical parameters, serum tests, or
pulmonary function studies.8 This pattern, however, is much
the same as most idiopathic interstitial pneumonias or other
fibrosing lung conditions. In IIPs an increase in BAL neutro-
phils (levels >5%) is noted in 70e90% of patients. The pres-
ence of a BAL neutrophilia increases the likelihood of an
underlying fibrosing process (IPF, fibrosing alveolitis of
rheumatological disease, asbestosis, or fibrotic sarcoidosis),
the proportions of neutrophils correspond to the extent of
reticular change on HRCT.9 BAL eosinophiliamay also bemild
or moderate. An associated increase in BAL eosinophils
(levels >2%) is apparent in 40e60% of IPF patients.10 When
eosinophils represent more than 20% of the count, consid-
eration should be given to an eosinophilic lung disease.11 An
increase in BAL lymphocytes is noted in 10e20% of IPF
patients. Lymphocytosis is not a feature of UIP, and counts
above 15% should alert to an alternative diagnosis such as
NSIP, cryptogenic organizing pneumonia, hypersensitivity
pneumonitis, sarcoidosis, drug-induced lung disease or other
granulomatous lung disease.1,12 In a recent study Ohshimo S
et al. showed that BAL lymphocytosis (>30%) changed
diagnostic perception in six of 74 patients who would have
been misdiagnosed as having IPF without BAL.13 This study
demonstrates that the addition of BAL to the diagnostic
procedures is useful in patients suspected of having IPF with
a confident CT diagnosis and consistent clinical features, in
the absence of a surgical biopsy. BAL cell differentials are of
additional diagnostic benefit in this clinical setting.
BAL and/or transbronchial biopsy were considered
requirements for the exclusion of other diseases in
a patient with IPF who did not undergo surgical lung biopsy
as one of the four major criteria for making a clinical
diagnosis of IPF according to the American Thoracic Society
(ATS)/European Respiratory Society (ERS) IPF Statement of
2000. In the ATS/ERS international consensus classification
of idiopathic interstitial pneumonias (IIPs) of 2002,2 BAL
analysis was no more found to be important in the diag-
nostic work-up of IPF. In that statement, a confident CT
diagnosis of IPF with consistent clinical features was
considered to be sufficient to make an accurate diagnosis of
IPF without surgical biopsy.
Key points
 A finding of raised neutrophils (>5%) and raised eosin-
ophils (>2%) is characteristic of IPF, but not diagnostic
 BAL is not required as a diagnostic tool in patients with
clinical features and HRTC appearances typical of IPF
 In IPF a lone increase in BAL lymphocytes or eosinophils
is uncommon and these observations may influence
diagnostic confidence
BAL in differential diagnosis and Co morbidity of
IPF
BAL is a non-invasive diagnostic procedure in interstitial
lung diseases (ILD), not only for the diagnosis of certain
S72 A. Pesci et al.non-IIP diseases such as hypersensitivity pneumonitis,
sarcoidosis, histiocytosis x or pulmonary alveolar protei-
nosis but also for the exclusion of infection or malignancy.1
In addition, the pattern of inflammatory cells identified
may be helpful in narrowing the differential diagnosis of
fibrosing interstitial pneumonias. When pulmonary infil-
trates are associated with immunosuppressive therapy, BAL
makes a crucial contribution to the detection of opportu-
nistic infection superimposed to lung fibrosis. Acute exac-
erbations of IPF are dramatic scenario characterized by
diffuse alveolar damage (DAD) superimposed on UIP. In this
condition the use of BAL may be contribute to the diagnosis
showing a pattern confident with DAD: no evidence of
pulmonary infection; neutrophilia (>50%); presence of
reactive type II pneumocytes.14e16
The differentiation between fibrotic NSIP and UIP, in
absence of surgical lung biopsy, is a difficult challenge for
physicians. After the first description of NSIP in 1994, BAL
lymphocytosis is more likely suggestive of NSIP rather than
UIP.1,2 A few recent studies have also shown that BAL could
provide substantial diagnostic information on UIP and
NSIP.1 A retrospective study was undertaken by Ryu et al.7
with fibrotic IIP (UIP 87/NSIP 35). They concluded that BAL
is an useful non-invasive tool in fibrotic IIP, not only for
excluding a variety of specific non-IIP diseases but also for
narrowing the differential diagnosis and predicting the
prognosis in the absence of an histopathologic diagnosis.
Particularly BAL lymphocytosis was more frequently
observed in NSIP than UIP while the absence of BAL
lymphocytosis suggested a diagnosis of UIP. The presence
of BAL neutrophilia, however, could not predict a diagnosis
of IPF. These results contrasted with the report by Veer-
araghavan et al.5 which concluded that the BAL findings in
54 patients with a clinical diagnosis of UIP had no diag-
nostic role in discriminating between UIP and NSIP. Also
Daniil et al.17 did not find a BAL lymphocytosis in a small
cohort of NSIP patients. BAL findings were compared
between UIP and fibrotic NSIP in a large cohort of patients
presenting with the clinical features of IPF. Welker et al3 in
a large study which aim was to quantify how the like hood
for a given diagnosis changes with the knowledge of BAL
cell differentials, concluded that BAL do not discriminate
between UIP and NSIP in patients presenting with clinical
features of UIP and have no prognostic value, once the
distinction between the two has been made histologically.
These data suggest that BAL differential cell count per se
provide substantial diagnostic information only in rela-
tively frequent diseases, such as sarcoidosis and UIP and
are less helpful in infrequent diseases (NSIP, etc.).
Therefore the role of BAL in fibrotic IIP is still
controversial.
Key points
- In patient with uncertain diagnosis, typical BAL cellular
profiles may allow a diagnosis of hypersensitivity pneu-
monia, pulmonary histiocytosis x, occupational dust
exposure, or sarcoidosis
- BAL in IPF should be considered in all patients with sus-
pected infection, malignancy or acute exacerbations. In
such cases, BAL may be diagnostic- The BAL cell count does not clearly differentiate
between fibrotic NSIP and UIP
- An increase in BAL lymphocytes is in favour of NSIP
(idiopathic or secondary)
BAL in prognosis and follow up of IPF
In the follow-up depicting prognosis and response to
treatment BAL fluid analysis has less clinical relevance.
There have been conflicting results in previous studies
evaluating the relationship between BAL fluid cellularity
and outcome.
In studies performed in IPF, prior to the recent reclas-
sification,2 it was demonstrated that higher BAL fluid
neutrophilia and/or eosinophilia predicted a subsequent
deterioration in pulmonary function test result parameters
or a poor response to therapy, whereas BAL fluid
lymphocytosis was associated with responsiveness to
therapy and better prognosis.18e23 However, these rela-
tionships are too inconsistent in individual patients for BAL
to be used as a reliable prognostic guide and, in addition,
all these studies were performed in IPF patients without
firm diagnostic criteria. In more recent study, Veerar-
aghavan et al.5 reported that BAL had neither diagnostic
role nor prognostic value in 54 patients with either IPF or
idiopathic NSIP. In a retrospective study Ryu et al.7 eval-
uated whether the BAL findings could predict the prognosis
in the absence of the histological diagnosis. They
concluded that BAL is an useful non-invasive tool in
fibrotic IIP, not only for excluding a variety of specific non-
IIP diseases but also for narrowing the differential diag-
nosis and predicting the prognosis in the absence of an
histopathologic diagnosis. In particular, the presence or
absence of BAL lymphocytosis was important, unless
pathologic diagnosis was confirmed, it can be an inde-
pendent predictor of good prognosis in fibrotic IIP. BAL
neutrophilia, however, did not have prognostic value in
this study. In another study of 81 IPF patients, BAL fluid
neutrophil and lymphocyte counts predicted mortality in
current smokers, but not among never smokers or former
smokers.6 A study of a large well characterized cohort of
IPF patients with comprehensive and long-term follow-up
showed that an increase in BAL fluid neutrophil percentage
was an independent predictor of early mortality.4 This
study found no significant interaction with smoking on the
association of BAL fluid neutrophil percentage and
mortality. Selman M et al24 evaluated the clinical behav-
iour and survival rate of IPF patients classified as “‘rapid”
or “‘slow” progressors according to the duration of
symptoms before diagnosis. IPF rapid progressors did not
have more BAL neutrophils and or eosinophils than slow
progressor, however, BAL from rapid progressors showed
a 2-fold increase of active matrix metalloproteinase-9, and
induced a higher fibroblast migration compared with slow
progressors and controls.
The value of serial BAL is limited, although it has been
incompletely studied. In one observational study of 32
patients followed with serial BAL for a median of four
years, patients with definite and sustained clinical
improvement had a reduction in serial lavage total cell
counts toward the normal range.25
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 Because of few and conflicting results BAL fluid analysis
has very little clinical relevance determining prognosis
and response to treatment in IPF
 The number and type of cells found in the BAL fluid
have no prognostic value and therefore serial BAL for
monitoring the disease progression or response to
treatment are not advised.
Conclusions
BAL is not always required in the assessment of IPF.
However, if, as is commonly the case, it has been per-
formed in diagnostic work-up of diffuse parenchymal lung
disease to exclude infection or tumor, the result may assist
in the decision to perform a surgical biopsy and in dis-
tinguishing different form of IIP. Although not diagnostic in
IIP, a “typical” BAL cell pattern strengthens the clinical
diagnosis and may contribute to the clinico-radiologic-
pathologic assessment in difficult cases. Even if the clin-
ical utility of BAL in IPF should be reconsidered, further
studies are needed to define the clinical utility of this
procedure in this intriguing disease.
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